Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. read more

EMPLOYEE PARTICIPANTS: 12

TOTAL RATINGS: 170

CEO: John Leonard

HR or Marketing? Claim Your Free Employer Account

Intellia Therapeutics Awards

Intellia Therapeutics has not won any awards as of yet. However, based on 170 ratings and 12 participants, employees at Intellia Therapeutics are satisfied with their work experience. The overall culture score, 77/100 or B+, incorporates employee ratings based on their feedback on the Team, CEO Rating, Manager and more. Also, Intellia Therapeutics ranks in the top 20% of similar size companies and top 30% of companies on Comparably

Awards

Comparably Awards are provided yearly to top performing company cultures based on real feedback from their employees.

Intellia Therapeutics hasn't won any awards yet.

Top

20%

Intellia Therapeutics currently ranks in the Top 20% of similarly sized companies on Comparably

Top

30%

Intellia Therapeutics currently ranks in the Top 30% of nearby companies

2nd

Intellia Therapeutics currently ranks 2nd place versus 4 competitors

Help Your Company Win 2025 Awards